Outlook Therapeutics' Lytenava Receives Final EMA Approval for Wet AMD Treatment
First Dedicated Ophthalmology Formulation of Bevacizumab Approved
The European Medicines Agency (EMA) has granted final approval for Lytenava (bevacizumab gamma) from Outlook Therapeutics (ticker: OTLK) as a treatment for neovascular (wet) age-related macular degeneration (nAMD). Lytenava is the first and only bevacizumab formulation specifically developed and manufactured for ophthalmic use, representing a significant advancement in the market. Previously, ophthalmologists had been using Avastin, a cancer drug, which was obtained from pharmacies and administered as needed, raising concerns about sterility and potential adverse effects such as severe intraocular inflammation. This approval marks a turning point, as it provides patients with access to a safe and standardized ophthalmic antibody drug.
Demonstrated Superior Efficacy in Phase 3 Clinical Trials
The primary mechanism of action of Lytenava involves targeting and binding to vascular endothelial growth factor-A (VEGF-A), thereby fundamentally inhibiting the formation of abnormal blood vessels in the retina. In the Phase 3 NORSE TWO trial (NCT03834753), Lytenava demonstrated remarkable clinical efficacy. At month 11 of treatment, 41.7% of patients in the Lytenava group achieved a primary endpoint of at least a 15-letter improvement in best-corrected visual acuity (BCVA), compared to 23.1% in the Lucentis (ranibizumab) control group, a statistically significant difference (p=0.0052). The secondary endpoint of mean visual acuity change also showed significant statistical improvement (p=0.0035), further confirming the drug's potent therapeutic effect.
Global Strategy to Penetrate the Off-Label Wet AMD Market
This approval represents a major commercial milestone for Outlook Therapeutics in the approximately $9.5 billion global wet AMD market, which has been dominated by off-label bevacizumab. Lytenava addresses the needs of healthcare professionals and regulatory authorities who are seeking safe and well-defined products. To ensure a smooth launch, Outlook Therapeutics has established a comprehensive commercial partnership with Cencora, a global healthcare distribution company, to build a robust supply chain. This proactive approach mitigates the risk of initial supply chain disruptions, which are common during new drug launches, and will facilitate rapid market access across Europe.
Plans for European Reimbursement and Expansion into the U.S. Market
To achieve substantial sales across Europe, Outlook Therapeutics is expediting price negotiations and reimbursement listing procedures in individual countries, starting with Germany and the United Kingdom. Lytenava has already been successfully launched in Germany and the United Kingdom in June 2025, and the company has recently entered into additional exclusive distribution agreements with local partners such as Mediconsult in Switzerland, further expanding its reach. In addition to Europe, the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the Biologics License Application (BLA), with a Prescription Drug User Fee Act (PDUFA) action date of July 29, 2026, making further growth in the global ophthalmology market even more promising.
In the approximately $9.5 billion global wet AMD market, Lytenava is expected to rapidly gain market share compared to existing high-cost targeted therapies such as Eylea and Lucentis, due to its strong price competitiveness and regulatory compliance. The impressive data from the Phase 3 NORSE TWO trial, which showed a 41.7% improvement in visual acuity (at least 15 letters) compared to 23.1% in the Lucentis control group (p=0.0052), will establish Lytenava as a reliable clinical alternative to the current practice of using off-label Avastin. Outlook Therapeutics has formalized its entry into the European market through its global 3PL and distribution partnership with Cencora, which is expected to set a new industry standard for safety in ophthalmic treatments. In the short term, the company will demonstrate revenue growth in Europe based on the commercial launches in Germany and the United Kingdom, as well as the distribution agreement in Switzerland. In the medium to long term, the FDA's PDUFA decision on July 29, 2026, will be a key factor in determining the valuation of Outlook Therapeutics.
Source: EMA (ema)